Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00912717 · ClinicalTrials.gov registry record
Pancreatic Adenocarcinoma Gene Environment Risk Study
A clinical trial of Pancreatic Cancer, sponsored by University of Pittsburgh.
- Recruiting
- Registry status
- 10,000
- Enrollment target
- 1
- Study location
NCT00912717: Recruiting study of Pancreatic Cancer, sponsored by University of Pittsburgh.
NCT00912717 is a study of Pancreatic Cancer that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 10,000 participants, above the 357-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (2701% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00912717, a study of Pancreatic Cancer, is actively recruiting participants, sponsored by University of Pittsburgh.
- RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 1
- Study location
Study Summary
After informed consent, participants will be asked to complete a medical/family history questionnaire and provide a blood sample. Some participants may also be asked to provide a urine sample. Individuals undergoing procedures that require collection of biological samples for clinical purposes may have these samples saved for research purposes. Participants will also be asked for their permission for study investigators to access medical records and/or recontact them for updates to their medical and family histories. Data and biospecimens will be stored for potential future research projects.
Conditions Studied
Study Locations (1)
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2004-01 |
| Est. Completion | 2027-12 |
What NCT00912717 shows while recruiting
NCT00912717 is an observational study that tracks outcomes without assigning an intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, above the 357-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (2701% higher).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00912717 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00912717 about?
NCT00912717 is a clinical study titled "Pancreatic Adenocarcinoma Gene Environment Risk Study". After informed consent, participants will be asked to complete a medical/family history questionnaire and provide a blood sample. Some participants may also be asked to provide a urine sample. Individuals undergoing procedures that require collection of biological samples for clinical purposes may h...
What is the current status of trial NCT00912717?
This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2004-01. Estimated completion is 2027-12.
What conditions does trial NCT00912717 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
Who is sponsoring clinical trial NCT00912717?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00912717 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00912717's enrollment target sits among peer trials
10,000 2nd of 278 the highest of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia